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Abstract 
Use of laser therapy in the treatment of pigmented lesions is a controversial issue, as it can 
delay melanoma diagnosis and may negatively impact mortality. Few cases of melanoma 
after laser therapy have been reported. It is still unknown whether melanoma can be induced 
by lasers.  
We discuss the outcomes of twelve patients presenting with melanoma subsequent to 
previous treatment with laser.  
In four patients, skin biopsy was performed before laser treatment. Histology was re-
evaluated by a panel of experienced dermatopathologists and analyzed in the context of 
clinical and photo-optical data. There was evidence for pathological misdiagnosis in two 
cases. The other two cases initially presented with non-suspicious features before laser 
treatment and were clearly diagnosed as melanoma thereafter, opening the possibility of 
melanoma induction by laser treatment. Most patients were female and presented with facial 
lesions. Three patients have already died of melanoma and two are in stage IV, showing 
progressive disease with distant metastases.  
Laser therapy is a common treatment for pigmented lesions, increasing the risk of delayed 
melanoma diagnosis. This prevents appropriate and timely therapy, and may therefore lead 
to a fatal outcome. A careful examination of all pigmented lesions using surface microscopy 
and representative biopsies in combination with a close follow-up is recommended.  
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Introduction 
Now that the basic principles of laser surgery have been established, various chromophores, 
e.g. melanin, can be targeted effectively with minimal injury to surrounding structures [1]. 
Today, lasers are successfully applied in the treatment of many medical conditions, 
preferentially in easily accessible organs such as the skin. There has been a notable and 
substantial increase in the number of applications of laser or similar devices in the western 
world; this is not restricted to physicians and can involve cosmetologists and aestheticians, 
for example. Melanin-specific, high-energy, quality-switched (QS) laser systems are able to 
lighten or eradiate epidermal and dermal pigmented lesions [2]. Nonetheless, the 
appropriateness of laser use in the treatment of melanocytic lesions continues to be debated. 
The incidence of melanoma is still rising in Caucasian populations [3], but early diagnosis is 
responsible for a plateau in melanoma mortality [4]. Laser therapy can delay melanoma 
diagnosis and may negatively impact mortality [5].  
This study identified 12 patients treated with laser and diagnosed with melanoma thereafter. 
Most patients were female and presented with facial lesions. In four cases, biopsies prior to 
laser treatment were available. There was evidence for pathological misdiagnosis in two 
cases that showed malignancy on re-evaluation. The other two cases presented with non-
suspicious features before laser treatment and were clearly diagnosed as melanoma 
thereafter, introducing the possibility of induction of melanoma by lasers.  
As only few cases of melanoma subsequent to previous treatment with laser have been 
reported, it is likely that our sample of 12 patients represents an underestimated medical 
problem that requires urgent attention from the medical community. 
Patients and methods 
From 1999 until 2007, all patients with melanoma and a history of laser treatment who 
presented at the University Hospital of Zurich were evaluated. This study used patient 
records to investigate melanoma development, outcome, and the time from laser treatment 
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to melanoma diagnosis. All histology was re-evaluated by a panel of experienced 
dermatopathologists and analyzed in the context of clinical and photo-optical data.  
Study Population 
Of the 12 patients studied, nine were female. The mean age was 55.08 years at the time of 
melanoma diagnosis. In four cases, a nodular malignant melanoma (NMM) occurred; four 
patients presented with lentigo maligna (LM) or lentigo maligna melanoma (LMM) and four 
with other melanoma types. Ten of the treated lesions were located on the face; the other 
two were located in the upper extremities (Table 1). Ablative lasers were used for all patients 
included in this sample, whereas, in cases from the literature, lesions were also treated with 
pigment-specific lasers.  
For the three patients who were already described in reports from 1999 and 2003 [5,6] an 
update is provided. 
Literature review 
A Pubmed literature review was performed using the words ‘melanoma, laser’ and ‘laser, 
pigmented lesion’ from 1986 to 2007. Identified articles were analyzed with special interest 
paid to patient histories, in order to identify the circumstances and the delay of melanoma 
diagnosis [5-16].   
Results 
In eight patients from our sample and five cases from the literature, no initial histological 
evaluation was performed prior to laser treatment [8,9,12,13]. Among them was the patient 
discussed in 1999 [5], who died of metastatic disease with pulmonary, cerebral, dermal, and 
abdominal metastases 84.33 months after laser therapy. 
Biopsies were performed before laser therapy in four patients from our sample [6] and in one 
case from the literature [8]; these were histologically diagnosed as non-suspicious and 
subsequently followed by laser treatment. In two of the cases from our retrospective sample 
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and in the case from the literature, histological re-evaluation of the biopsies after melanoma 
diagnosis identified a malignant process. In the other two patients from our retrospective 
sample, biopsies were considered non-suspicious even though sample size and quality were 
limited and possibly not appropriate for a reliable diagnosis [6]. One of those, the patient 
described in 2003 showed a nodular melanoma five years after the initial shave-biopsy of a 
benign melanocytic naevus, which was retrospectively confirmed as benign. This patient 
developed multiple intrapulmonary, soft tissue and brain metastases [6].  
In one patient from our sample and three cases from the literature, lentigo maligna was 
treated with laser [7,12,14]. 
Case studies 
Case 1  
A 52-year-old female patient presented to us in 2003 with a newly diagnosed, unclassifiable 
malignant melanoma on her right cheek (Fig. 1C and 1D). Breslow's index was 2.6 mm, the 
Clark level was IV, and the sentinel node biopsy was negative. The medical history revealed 
several carbon dioxide- (CO2 -) and erbium-laser treatments of the lesion over the past six 
years. The lesion had existed since mid-1996 and was clinically diagnosed as a seborrheic 
keratosis by a dermatologist in 1997. After the third laser treatment, a biopsy of the relapse 
was performed with a histological diagnosis of a junctional melanocytic naevus. The initial 
histological diagnosis was reviewed retrospectively and confirmed by a panel of experienced 
dermatopathologists, although the sample size and quality were limited (Fig. 1A and 1B).  
The patient now participates in our constant aftercare with no sign of metastasis and stage 
IIA disease (T3aN0M0).  
Case 2  
A 72-year-old male patient first presented to us in 2006 with several histologically confirmed 
dermal satellite metastases on his forehead (Fig. 2D). Six months earlier, a lentigo maligna 
 6
with conversion to lentigo maligna melanoma was diagnosed with a Breslow's index of 2.8 
mm and a Clark level of V. Sentinel lymph node was negative.  
Two years earlier, a pigmented skin lesion considered to be a melanocytic naevus (Fig. 2A) 
was excised from the same location with external pathological diagnosis of melanocytic 
naevus with moderate atypia. After this diagnosis, the lesion was treated with laser. Despite 
the limited sample size and quality, re-evaluation by a panel of experienced 
dermatopathologists after the melanoma diagnosis revealed atypical melanocytes over 
actinically damaged skin that was considered to be melanoma in situ (Fig. 2B and 2C).  
Pulmonary metastases during treatment with dacarbazine and a progressive course of 
cerebral metastases under vindesine and interferon alfa-2a led to the patient’s death. 
Outcome 
In our patients, we observed a time from laser treatment to melanoma diagnosis ranging 
from 5.75 to 84 months, with a mean time of 33.33 months (Table 1). The interval between 
first excision with diagnosis of a benign process and excision of a melanoma ranged 
between 1.84 and 135.68 months. From first appearance of the skin lesion to laser therapy, 1 
to 132 months passed. In one patient, a lesion at this location had existed since childhood.  
 
The diseases of seven patients are in complete remission. Two patients are in stage IV, 
showing distant metastases at follow-up. The survival of these patients (first distant 
metastasis to follow-up) is 60 and 75 months. Three patients have already died from 
melanoma with survival times (first distant metastasis to death) of 9, 20 and 22 months.  
 
Cases in the literature 
The 12 patients published in the literature with melanoma subsequent to previous treatment 
with laser were treated with QS-ruby laser or with ablative devices [5-16]. Likewise to our 
findings, with ablative laser treated patients only, the average interval between laser 
treatment and melanoma excision was 36.1 months. The time from first excision to diagnosis 
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of malignant melanoma ranged from 18 to 144 months (data not shown). The interval from 
first appearance of skin lesions to laser therapy was only described for three patients in the 
literature: 120 months for two patients [8,14], and 72 months for another patient [13]. Follow-
up data were rarely assessed in the literature, and in half of the cases, no clinical outcome 
was mentioned.  
Discussion 
Based on our observations, together with published information, we assume a biologically 
relevant delay in melanoma diagnosis due to laser treatment, retarding appropriate staging 
and therapy. The circumstances of the cases are varied.  
Clinical misdiagnosis 
When laser treatment is performed without any initial histological evaluation, a clinical 
misdiagnosis can be assumed since every 200th pigmented lesion excised as a melanocytic 
naevus turns out to be a malignant melanoma [9]. Three-quarters of lesions in people without 
preserved biopsy specimens were located on the face (10/13), and two-thirds (9/13) were in 
female patients [5,8,9,12,13]. It can therefore be assumed that laser treatment was chosen 
for aesthetic reasons. The widespread use of lasers for this purpose is alarming [17], 
considering the fatal outcome in two of these patients. 
Histological misdiagnosis 
Determination of initially non-suspicious histological findings as malignant upon re-evaluation 
might be due to limited sampling. Laser therapy is only indicated in selective cases and only 
after collection and preservation of histological specimens [8]. However, limited sampling 
might be inadequate for accurate histological diagnosis of pigmented melanocytic lesions on 
actinically damaged skin [11,18]. Thus, it remains unclear whether punch and shave biopsy 
techniques are sufficient to rule out malignancy [18]. 
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Benign process before laser treatment  
There are several possible explanations for melanoma development in patients who had a 
histological diagnosis of a benign process before melanoma excision, including the possibility 
of melanoma induction by lasers.  
The laser treatment may have been inadequate for destruction of the entire lesion [13]. 
Superficial biopsies are suboptimal, as the boundaries of deep margins cannot be fully 
ascertained [19]. Areas chosen for biopsy may fail to reveal the foci of invasive melanoma 
within a lesion [18]. Deeper intrafollicular melanocytes may not receive sufficient energy 
when treated with QS-laser systems, thus allowing for recurrence [13]. Ablative systems 
such CO2 and argon lasers are not pigment-specific and carry a special risk of relapse [20]. 
In our series, all patients were treated with ablative laser devices. Incomplete surgical 
removal [21] as well as laser treatment [22] of benign melanocytic naevi may result in 
histological features of so-called pseudo-melanoma. Such recurrent pigmented lesions 
clinically as well as histologically resemble superficially spreading melanoma. Even histology 
may not always distinguish malignant from benign in those cases.   
To date, there has been no directly demonstrated correlation between laser treatment and 
malignant transformation of dysplastic naevi [23]. Helium-neon laser treatment leads to 
proliferation in melanoma cells [24]. Sub-lethal laser damage to melanoma cells led to an 
increased p16 level, implying that DNA damage had taken place [25]. Relapse of congenital 
naevi after QS-alexandrite-laser treatment might be due to proliferation of melanocytes after 
down-regulation of E-cadherin and TNF-alpha [26]. It remains unclear whether QS-ruby 
lasers (QSRL) are able to transform benign melanocytes into malignant ones [13]. Hafner 
and co-workers investigated the impact of QSRL on primary melanocytes and showed that 
laser treatment does not result in major alterations of global gene expression, particularly in 
genes associated with melanoma [27]. 
 9
Lentigo maligna treated with laser 
Lentigo maligna (LM) is an in situ melanoma in UV-damaged skin of patients with advanced 
age. The clinical hallmark of LM is very slow but steady and continuous horizontal expansion 
of atypical melanocytes which tend to diverge into subclones. These subclones can be 
identified by pigmentation changes which give the lesion a heterogeneous pigmentation 
pattern. Non-surgical methods in the treatment of LM may be associated with higher 
recurrence rates. Melanocytes in LM may not respond to pigment-specific wavelengths due 
to a loss of pigment production ability [14]. Lasers only damage the superficial skin, creating 
a scar. This conceals the incompletely destroyed tumour, which might result in unnoticed, 
deep infiltrative growth of the residual tumour [12]. Niiyama and co-workers assume the 
possibility of laser influence on the progression from LM to LMM [14]. The possibility of 
sampling errors might be more likely, as LM tends to be large and invasive foci may be 
missed due to partial excision.  
From a molecular point of view, continuous expansion must be considered immortalization of 
melanocytes while clonal divergence is a sign of enhanced mutation rate within the 
melanocyte population which is the prerequisite of further malignant progression. On the 
other hand, histological changes may be very subtle in LM and not present in all areas of the 
lesion. Therefore, a facial pigmented lesion which recurs after destructive treatment, as 
described in case 1, should be considered suspicious of LM as relapse after laser treatment 
could be a sign of melanocyte immortalization. Likewise, a heterogeneous pigmentation 
pattern as demonstrated by figure 2A is equally suspicious of LM. Complete excision should 
be the treatment of choice for achieving accurate microstaging and reducing the likelihood of 
recurrence in LM [28].  
 
Use of laser therapy in the treatment of pigmented lesions, e.g. lentigines and melanocytic 
naevi, is common and increases the risk of delayed melanoma diagnosis, thus preventing 
timely and appropriate therapy. This may lead to a fatal outcome. We believe that this 
medical problem is underreported. A careful examination of all pigmented lesions using 
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surface microscopy and representative biopsies in combination with a close follow-up is 
recommended. The development of melanoma subsequent to laser treatment of 
histologically documented benign lesions introduces the possibility of melanoma induction by 
lasers.  
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Table 
Table 1 Clinical findings in 12 patients.  
          
 Patient 
number  Sex 
Age 
(years) 
Initial clinical 
evaluation 
Lesion 
location Laser type 
Melanoma 
type 
Laser treatment to 
melanoma diagnosis 
(months) 
 
 1 f 52 Seborrheic keratosis  Cheek CO2, Erbium n.c. 80.94  
 2 m 72 Melanocytic naevus Forehead n/a LMM 20.00  
 3 m 66 Lentigo Cheek CO2 LM 84.00  
 4 f 75 n/a Praeauricular CO2 LM n/a  
 5 f 63 Melanocytic naevus Mandibular n/a SSM 6.41  
 6 f 46 Melanocytic naevus Eyebrow n/a n/a 9.00  
 7 m 47 Verruca vulgaris Praeauricular CO2 NMM 12.20  
 8 f 21 Melanocytic naevus Upper arm n/a ALM 12.00  
 9 f 45 Verrucous naevus Forehead n/a NMM 5.75  
 10 f 59 Lentigo solaris Cheek Erbium:YAG LMM 34.29  
 11 f 75 Basal cell carcinoma Upper arm CO2 NMM 18.00  
 12 f 40 Lentigo maligna Under lower lip CO2 NMM and ALM 84.00  
Abbreviations: f, female; m, male; n/a, not applicable; LMM, lentigo maligna melanoma; ALM, acrolentiginous 
melanoma; LM, lentigo maligna; SSM, superficial spreading melanoma; NMM, nodular malignant melanoma; n.c., 
not classifiable;  YAG, Yttrium-aluminium-garnet; CO2, carbon dioxide.   
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Legends for figures 
Fig. 1. Hematoxylin and eosin stained histological sample from patient 1 after the third laser 
treatment, in overview (A) and detail (B): focal pigmented junctional melanocytic naevus. 
Melanoma at point of diagnosis six years after first laser treatment, three years after naevus 
excision, in overview (C) and detail (D). 
 
Fig. 2. (A) Lesion on the forehead of patient 2 prior to sample excision and laser treatment. 
(B) Biopsy prior to laser treatment, already showing limited sample size and quality. (C) 
Lesion in detail showing atypical naevus over actinically damaged skin considered as 
melanoma in situ. Melanoma with dermal satellite metastases (arrow) two years after laser 
treatment (D). 
 
